Cancer Family
Central Nervous System Neoplasm
CI-CAN-00000118Explore in graph →
Non-malignant1,345 active trials7 approved drugs177 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000118Explore in graph →
Clinical trials
5,060 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03678389 | Feasibility of Endosphenoidal Coil Placement for Imaging of the Sella During Transsphenoidal Surgery | recruiting | N/A | 70 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05355701 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | active not recruiting | Phase 1 | 103 | PfizerINDUSTRY | 3 | Sep 1, 2026 |
| NCT05538130 | A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | active not recruiting | Phase 1 | 148 | PfizerINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT06161974 | Study of Olutasidenib and Temozolomide in HGG | recruiting | Phase 2 | 60 | Rigel PharmaceuticalsINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07242963 | Relapsed and Progressive Sonic Hedgehog Medulloblastoma With U1 Mutation Registry Study | recruiting | — | 300 | Mohammad H. Abu ArjaOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07797660 | A Study for Postoperative Delirium in Older Patients With Intracranial Tumors | not yet recruiting | — | 164 | Beijing Tiantan HospitalOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04145115 | A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden | active not recruiting | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT05226494 | Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma | active not recruiting | Phase 1 | 34 | NanoPharmaceuticals LLCINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT05489783 | Glioma Developmental and HyperActive Ras Tumor (DHART) Board | recruiting | — | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07793994 | Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors | not yet recruiting | N/A | 130 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796061 | Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)(LIFT) | not yet recruiting | Phase 1 | 45 | Children's National Research InstituteOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02179086 | Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 624 | NRG OncologyOTHER | 2 | Aug 28, 2026 | clinicaltrials |
| NCT02639325 | Tumor Related Epilepsy | recruiting | — | 100 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02867592 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | active not recruiting | Phase 2 | 109 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04181684 | LITT Followed by Hypofractionated RT for Recurrent Gliomas(GCCC 19140) | active not recruiting | N/A | 39 | University of Maryland, BaltimoreOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)(SIGMA) | recruiting | Phase 3 | 365 | Nuvation Bio Inc.INDUSTRY | 3 | Aug 28, 2026 | clinicaltrials |
| NCT05588141 | A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | recruiting | Phase 1 / Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07278440 | An Exercise Intervention for Improving Mental and Physical Health in Patients With Primary Brain Tumors and Their Caregivers, ET-NEURO Trial | recruiting | N/A | 36 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07282470 | Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND(MIND) | active not recruiting | — | 210 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07420543 | Clinical Significance of Liquid Biopsy in Brain Tumor Patients: a 5-ALA Guided Approach(FLUO-LB) | active not recruiting | — | 30 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07781852 | Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | not yet recruiting | Early Phase 1 | 40 | Lumina Pharmaceuticals IncINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT04464200 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | active not recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04794972 | A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors | recruiting | Phase 1 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT06474533 | Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm | recruiting | — | 199 | Thomas HopeOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07409584 | Mental Health and Suicidality in Glioblastoma Patients in Germany(SHINE-GLIO) | recruiting | — | 180 | University Hospital, EssenOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789379 | Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma | not yet recruiting | Phase 2 | 94 | Wei JiangOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07789938 | Intraoperative Neurophysiological Monitoring in Brain Tumor Surgery: Prospective Cohort Studies | not yet recruiting | N/A | 166 | Odense University HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07791264 | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma | not yet recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03048084 | Seizure Treatment in Glioma(STING) | recruiting | Phase 4 | 120 | Leiden University Medical CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05236036 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | active not recruiting | Phase 1 | 86 | Northwestern UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06557512 | Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma(SRS-AIM) | recruiting | N/A | 23 | University of California, San FranciscoOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06701812 | Digoxin Medulloblastoma Study | recruiting | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07778602 | Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas | not yet recruiting | Early Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Aug 26, 2026 | clinicaltrials |
| NCT07788430 | Impact of Pesticide Exposure on Survival and Tumor Aggressiveness in Patients With Glioblastoma: A Prospective Clinical Study(EXPOGLIO) | not yet recruiting | N/A | 120 | Institut Claudius RegaudOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07788677 | Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)(TARLAGLIA) | not yet recruiting | Phase 1 | 10 | Vall d'Hebron Institute of OncologyOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | recruiting | — | 75,000 | Children's Oncology GroupNETWORK | 6 | Aug 25, 2026 | clinicaltrials |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | recruiting | Phase 3 | 5,951 | Children's Oncology GroupNETWORK | 5 | Aug 25, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT05382338 | A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | recruiting | Phase 3 | 225 | Children's Oncology GroupNETWORK | 2 | Aug 25, 2026 | clinicaltrials |
| NCT05504291 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | recruiting | Phase 2 | 26 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT05948813 | TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases | recruiting | Phase 2 | 420 | TYK Medicines, IncINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06368817 | A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | recruiting | Phase 2 | 240 | Children's Oncology GroupNETWORK | 3 | Aug 25, 2026 | clinicaltrials |
| NCT07076472 | Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma | recruiting | Early Phase 1 | 8 | Mayo ClinicOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07437820 | Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases(NeoSRS) | not yet recruiting | N/A | 68 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07579208 | A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 1, 2026source: clinicaltrials